The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression
- PMID: 32130704
- DOI: 10.1007/978-3-030-34025-4_14
The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression
Abstract
The human body requires a constant delivery of fresh blood cells that are needed to maintain body homeostasis. Hematopoiesis is the process that drives the formation of new blood cells from a single stem cell. This is a complex, orchestrated and tightly regulated process that occurs within the bone marrow. When such process is faulty or deregulated, leukemia arises, develops and thrives by subverting normal hematopoiesis and availing the supplies of this rich milieu.In this book chapter we will describe and characterize the bone marrow microenvironment and its key importance for leukemia expansion. The several components of the bone marrow niche, their interaction with the leukemic cells and the cellular pathways activated within the malignant cells will be emphasized. Finally, novel therapeutic strategies to target this sibling interaction will also be discussed.
Keywords: Bone marrow; Dual-targeting; Hematopoiesis; Leukemia; Microenvironment; Signaling pathways.
References
-
- Agarwal P, Bhatia R (2015) Influence of bone marrow microenvironment on leukemic stem cells: breaking up an intimate relationship. Adv Cancer Res 127:227–252. https://doi.org/10.1016/bs.acr.2015.04.007 . S0065-230X(15)00035-4 [pii] - DOI - PubMed
-
- Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185(1):111–120. https://doi.org/10.1084/jem.185.1.111 - DOI - PubMed - PMC
-
- Andersson ER, Sandberg R, Lendahl U (2011) Notch signaling: simplicity in design, versatility in function. Development 138(17):3593–3612. https://doi.org/10.1242/dev.063610 . 138/17/3593 [pii] - DOI - PubMed
-
- Andreeff M, Zeng Z, Kelly MA, Wang R-y, McQueen T, Duvvuri S, Nowshah G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian HM, Konopleva M (2012) Mobilization and elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) stem/progenitor cells by Plerixafor/G-CSF/Sorafenib: results from a phase I trial in relapsed/refractory AML patients. Blood 120:142 - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
